← Back to patent-cliff list
KET-AD
Tier C — Watch / tradeKET-AD
Neurocentrx Pharma Pty Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR
Indications (approved)：Mania
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of KET-AD?
Approved indications include: Mania.
When does the KET-AD patent expire?
No public expiry year is available for KET-AD yet; this page updates once verified.
How do I get a quote for KET-AD intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29